Imugene Limited

    Everything you Need to Know about Investing in Health Stocks; 3 related players to Watch- NEU, PXS, CPH

    A Deep Dive into Imugene’s Opportunities in the Immuno-oncology Market

    Imugene Limited (ASX: IMU) is a clinical stage biotechnology company that focuses on the development of immunotherapies that have the potential to enable a...

    Imugene Goes Great Guns with Strong Management Team

    Imugene Limited (ASX: IMU), an Australian-headquartered clinical-stage immuno-oncology company, focusses on the development of emerging immunotherapies to enhance the efficacy of cancer treatments. The...

    A Glance at Imugene’s B-Cell Vaccine Developments in 2019

    An Australian-headquartered clinical stage biotechnology company, Imugene Limited (ASX: IMU) seeks to develop different novel immunotherapies to boost the efficacy of cancer treatments. Imugene’s...
    Imugene Releases Bioshares

    Imugene Releases Bioshares Presentation and Quarterly Updates; Stock Zooms up

    An emerging leader in cancer immuno-oncology, Imugene Limited (ASX: IMU) is a clinical stage biotechnology company seeking to develop a range of novel immunotherapies...

    An Overview Of IMU’s B-Cell Vaccines’ Clinical Trials

    An Australian-based biotechnology company, Imugene Limited (ASX: IMU) focuses on the development of cancer immunotherapies targeted at activating the immune system of cancer patients....

    Imugene Expands Immunotherapy Platform, Announces Licensing of Oncolytic Virus CF33 from City of Hope...

    A biotech company headquartered in Australia, Imugene Limited (ASX: IMU) develops new and novel immunotherapies that seek to harness the cancer patients’ immune system...
    Imugene Presents New HER-Vaxx Data At ESMO World Congress On Gastrointestinal Cancer

    Imugene Presents New HER-Vaxx Data At ESMO World Congress On Gastrointestinal Cancer

    A biotechnology company listed on the Australian Stock Exchange (ASX), Imugene Limited (ASX: IMU) develops cancer immunotherapies targeting B-cell peptide vaccines. The immunotherapies developed...

    A Look at Imugene’s robust pipeline of B-Cell Vaccines for Cancer Immunotherapy

    An Australian-headquartered clinical stage immuno-oncology company, Imugene Limited (ASX: IMU) has a robust pipeline of B cell vaccines aimed at treating a variety of...
    IMU

    An Insight into Imugene’s Unique Platform Technology

    Imugene Limited (ASX: IMU) is a clinical-stage immuno-oncology company headquartered in Australia that is engaged in developing a range of immunotherapies used to treat...

    A Glimpse At Biotech Company, Imugene Limited

    A biotechnology company with operations in America and Europe, Imugene Limited (ASX: IMU) deals with the development of cancer immunotherapies targeting B-cell peptide vaccines....

    Recent News